Treatment of cancers using anti-NKG2A agents

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10329348
APP PUB NO 20170313773A1
SERIAL NO

15521401

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INNATE PHARMAMARSEILLE FRANCE MARSEILLE BOUCHES-DU-RHONE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Andre, Pascale Marseilles, FR 31 339
Blery, Mathieu Marseilles, FR 25 157
Soulas, Caroline Marseilles, FR 6 64
Wagtmann, Nicolai Cassis, FR 33 179

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 25, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 25, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00